Monopar Therapeutics Inc. (MNPR)
NASDAQ · Healthcare
Monopar Therapeutics Inc. Shareholder Equity 2016–2025
Monopar Therapeutics Inc. annual shareholder equity history from 2016 to 2025. Shareholder equity represents the net worth of a company, calculated as total assets minus total liabilities.
- Monopar Therapeutics Inc. shareholder equity as of December 31, 2025: 137.8M, a 150.43% increase year-over-year.
- Monopar Therapeutics Inc. shareholder equity for 2025 were 137.8M, a 150.43% increase from 2024.
- Monopar Therapeutics Inc. shareholder equity for 2024 were 55.0M, a 335.84% increase from 2019.
- Monopar Therapeutics Inc. shareholder equity for 2019 were 12.6M, a 82.53% increase from 2018.
- Monopar Therapeutics Inc. shareholder equity for 2018 were 6.9M.
Shareholder Equity
ANNUAL · $B
YEAR-OVER-YEAR GROWTH · %
| Monopar Therapeutics Inc. Annual Shareholder Equity (Millions of US $) | |
|---|---|
| 2025 | $138 |
| 2024 | $55 |
| 2019 | $13 |
| 2018 | $7 |
| 2017 | $10 |
| 2016 | $3 |
Monopar Therapeutics Inc. Shareholder Equity — FAQ
Monopar Therapeutics Inc. (MNPR) shareholder equity over the last 6 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MNPR's shareholder equity history?
The chart and table above show Monopar Therapeutics Inc.'s shareholder equity by year and by quarter, including the growth rate.